— Daniel Schultz, commenting on the FDA's increased emphasis on post-approval surveillance, CDRH's Schultz outlines his 2008 action plan for agency," pp. 1, 5.
Subscribe to BioWorld™ news services
— Daniel Schultz, commenting on the FDA's increased emphasis on post-approval surveillance, CDRH's Schultz outlines his 2008 action plan for agency," pp. 1, 5.